-
- Umberto Tirelli.
- Recenti Prog Med. 2014 May 1; 105 (5): 181-3.
AbstractThe approval of new antiviral agents and the wide-ranging costs of ophthalmic therapies with comparable efficacy have renewed the debate over the cost-effectiveness of novel drugs. In oncology, more expensive treatments do not always substantially change the outcome of the disease, but they merely prolong life expectancy by a few weeks even at the cost of significant side effects. Treatment costs are a key factor the physician should consider when sharing care decisions with the patient. In addition, fund allocation for purchasing high cost medications results in limited investment in clinical research and human resources - doctors, nurses and other healthcare staff - that play a central role in patient care. Regulatory agencies should be more demanding, reimbursing pharmaceutical companies on the basis of treatment outcome.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..